For instance, genetic knockout of Gipr decreased LV remodeling and improved survival of mice after experimental myocardial infarction [10], whereas conversely human GIP has been reported to attenuate angiotensin II-induced cardiac hypertrophy and fibrosis [50]. The gene discussed is GIP; the disease is cardiac hypertrophy.